NEWS
Kairos Pharma Enters Agreement With Precheck Health Services to Develop Biomarkers to Identify Patients Responsive to Env105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
Kairos Pharma (NYSE American: KAPA)has entered a collaboration with PreCheck Health Services Inc. to develop companion biomarkers for its cancer therapy, ENV105, targeting prostate and lung cancers. The partnership aims to enhance patient screening and therapy monitoring for Kairos Pharma's Phase 1 and Phase 2 clinical trials.
PreCheck will analyze biopsy tissues and circulating tumor cells from patients in ongoing trials, including a Phase 2 randomized trial in prostate cancer and a Phase 1 trial in lung cancer. The collaboration will use PreCheck's SolidTumorCheck+ platform for gene expression profiling of tumor biopsies.
The partnership focuses on developing an FDA-approved companion diagnosticfor ENV105, which will help identify suitable patients for treatment in Phase 3 clinical trials. This collaboration is expected to advance personalized cancer treatment and improve patient outcomes.
PreCheck will analyze biopsy tissues and circulating tumor cells from patients in ongoing trials, including a Phase 2 randomized trial in prostate cancer and a Phase 1 trial in lung cancer. The collaboration will use PreCheck's SolidTumorCheck+ platform for gene expression profiling of tumor biopsies.
The partnership focuses on developing an FDA-approved companion diagnosticfor ENV105, which will help identify suitable patients for treatment in Phase 3 clinical trials. This collaboration is expected to advance personalized cancer treatment and improve patient outcomes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2012Followers
101Following
17KVisitors
Follow
Trytosaveabit : Some had a bit of advance notice again it appears? Hehehe
Jaguar8 OP Trytosaveabit : Yup Grrr